Asawanonda 2006.

Study characteristics
Methods	RCT, active placebo‐controlled, double‐blind Date of study: not reported Location: Bangkok, Thailand, Asia
Participants	Randomised: 24 participants (mean age 40 years (methotrexate) 48 years (placebo), 15 male) Inclusion criteria Participants with moderate‐severe plaque type psoriasis (BSA ≥ 20) Exclusion criteria Pregnancy, immunosuppression, alcohol abuse Dropouts and withdrawals 4 (17%) Time and reasons: conflicts in schedule (1 methotrexate group, 3 placebo group)
Interventions	Intervention A. Methotrexate (n = 11), 15 mg/week, orally Control B. Placebo (n = 13), orally Co‐intervention: phototherapy UVB
Outcomes	Assessment at 24 weeks Primary outcomes of the trial PASI 90 Secondary outcomes of the trial Time to relapse after clearance
Notes	Funding: (quote p 1013) no funding source Declarations of interest: (quote p 1013) "None identified"
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote (p 1014): "randomized by way of randomization cards" Comment: probably done
Allocation concealment (selection bias)	Unclear risk	Comment: no description of the method used to guarantee allocation concealment
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote (p 1014): "to receive either MTX or placebo, which were identical in appearance" Comment: probably done, placebo‐controlled
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote (p 1015): "PASI scores were given by a investigator blinded to the treatment assignment" Comment: probably done, placebo‐controlled
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Randomly assigned 24, analysed 24 Management of missing data: Comment: no more precision regarding methods for dealing with missing data
Selective reporting (reporting bias)	Unclear risk	Comment: no protocol available. The outcomes mentioned in the Methods section appeared to have been reported.